nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

25.06.2021 | Original Article

State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis

verfasst von: Martina Sollini, Margarita Kirienko, Fabrizia Gelardi, Francesco Fiz, Noemi Gozzi, Arturo Chiti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Fibroblast activation protein-α (FAPα) is overexpressed on cancer-associated fibroblasts in approximately 90% of epithelial neoplasms, representing an appealing target for therapeutic and molecular imaging applications. [⁶⁸ Ga]Ga-labelled radiopharmaceuticals—FAP-inhibitors (FAPI)—have been developed for PET. We systematically reviewed and meta-analysed published literature to provide an overview of its clinical role.

Materials and methods

The search, limited to January 1st, 2018–March 31st, 2021, was performed on MedLine and Embase databases using all the possible combinations of terms “FAP”, “FAPI”, “PET/CT”, “positron emission tomography”, “fibroblast”, “cancer-associated fibroblasts”, “CAF”, “molecular imaging”, and “fibroblast imaging”. Study quality was assessed using the QUADAS-2 criteria. Patient-based and lesion-based pooled sensitivities/specificities of FAPI PET were computed using a random-effects model directly from the STATA “metaprop” command. Between-study statistical heterogeneity was tested (I²-statistics).

Results

Twenty-three studies were selected for systematic review. Investigations on staging or restaging head and neck cancer (n = 2, 29 patients), abdominal malignancies (n = 6, 171 patients), various cancers (n = 2, 143 patients), and radiation treatment planning (n = 4, 56 patients) were included in the meta-analysis. On patient-based analysis, pooled sensitivity was 0.99 (95% CI 0.97–1.00) with negligible heterogeneity; pooled specificity was 0.87 (95% CI 0.62–1.00), with negligible heterogeneity. On lesion-based analysis, sensitivity and specificity had high heterogeneity (I² = 88.56% and I² = 97.20%, respectively). Pooled sensitivity for the primary tumour was 1.00 (95% CI 0.98–1.00) with negligible heterogeneity. Pooled sensitivity/specificity of nodal metastases had high heterogeneity (I² = 89.18% and I² = 95.74%, respectively). Pooled sensitivity in distant metastases was good (0.93 with 95% CI 0.88–0.97) with negligible heterogeneity.

Conclusions

FAPI-PET appears promising, especially in imaging cancers unsuitable for [¹⁸F]FDG imaging, particularly primary lesions and distant metastases. However, high-level evidence is needed to define its role, specifically to identify cancer types, non-oncological diseases, and clinical settings for its applications.

Nur mit Berechtigung zugänglich

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–6.PubMedCrossRef

Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities EMT: a naturally occurring transdifferentia-tion program. Front Med. 2018;12:1–13.CrossRef

Busek P, Mateu R, Zubal M, Kotackova L, Sedo A. Targeting fibroblast activation protein in cancer - Prospects and caveats. Front Biosci (Landmark Ed). 2018;23:1933–68.CrossRef

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59.

LeBleu VS, Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. DMM Dis Model Mech. 2018;11:1–9.

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146:895–905.PubMedCrossRef

Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57.PubMedPubMedCentralCrossRef

Calais J. FAP: The next billion dollar nuclear theranostics target? J Nucl Med. 2020;61:163–5.PubMedCrossRef

Tillmanns J, Hoffmann D, Habbaba Y, Schmitto JD, Sedding D, Fraccarollo D, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol. 2015;87:194–203.PubMedCrossRef

10.

Levy MT, McCaughan GW, Marinos G, Gorrell MD. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver. 2002;22:93–101.PubMedCrossRef

11.

Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A. 1992;89:10832–6.PubMedPubMedCentralCrossRef

12.

Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever O, et al. Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol. 2016;10:40–58.PubMedCrossRef

13.

Sedo A. Targeting fibroblast activation protein in cancer ndash Prospects and caveats. Front Biosci. 2018;23:4682.CrossRef

14.

Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. Green J, editor. PLoS One. Public Library of Science; 2015;10:e0116683.

15.

Ebert LM, Yu W, Gargett T, Toubia J, Kollis PM, Tea MN, et al. Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clin Transl Immunol. John Wiley & Sons, Ltd; 2020;9:e1191.

16.

Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160–7.PubMedCrossRef

17.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.PubMedPubMedCentralCrossRef

18.

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jäger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. Society of Nuclear Medicine and Molecular Imaging; 2018;59:1423–9.

19.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.PubMedCrossRef

20.

Deeks JJ, Altman DG. Sensitivity and specificity and their confidence intervals cannot exceed 100%. BMJ BMJ. 1999;318:193–4.PubMedCrossRef

21.

Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. Arch Public Health; 2014;72:39.

22.

von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35.CrossRef

23.

Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedPubMedCentralCrossRef

24.

Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein–targeted PET/CT with 68 Ga-FAPI for imaging IgG4-related disease: comparison to 18 F-FDG PET/CT. J Nucl Med. 2021;62:266–71.PubMedCrossRef

25.

Siebermair J, Köhler MI, Kupusovic J, Nekolla SG, Kessler L, Ferdinandus J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02307-w.

26.

Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Götz TI, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79:1485–91.PubMedCrossRef

27.

Röhrich M, Floca R, Loi L, Adeberg S, Windisch P, Giesel FL, et al. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. Eur J Radiol. 2020;127:109021.PubMedCrossRef

28.

Windisch P, Röhrich M, Regnery S, Tonndorf-Martini E, Held T, Lang K, et al. Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol. 2020;150:159–63.PubMedCrossRef

29.

Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13.

30.

Röhrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, et al. Impact of 68Ga-FAPI PET/CT Imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779–86.PubMedCrossRef

31.

Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020;47:2836–45.PubMedPubMedCentralCrossRef

32.

Ferdinandus, J., Kessler, L., Hirmas, N. et al. Equivalent tumor detection for early and late FAPI-46 PET acquisition. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05266-7.

33.

Serfling S, Zhi Y, Schirbel A, Lindner T, Meyer T, Gerhard-Hartmann E, et al. Improved cancer detection in Waldeyer’s tonsillar ring by 68Ga-FAPI PET/CT imaging. Eur J Nucl Med Mol Imaging. 2021;48:1178–87.PubMedCrossRef

34.

Bergmann C, Distler JHW, Treutlein C, Tascilar K, Müller A-T, Atzinger A, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. 2021;3:e185–94.CrossRef

35.

Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, et al. Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT. Front Cardiovasc Med. 2021;8:614997. https://doi.org/10.3389/fcvm.2021.614997.

36.

Liermann J, Syed M, Ben-Josef E, Schubert K, Schlampp I, Sprengel SD, et al. Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer. Cancers (Basel). 2021;13:796.CrossRef

37.

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–32.PubMedCrossRef

38.

Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48:1944–55.PubMedCrossRef

39.

Qin C, Liu F, Huang J, Ruan W, Liu Q, Gai Y, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05255-w.

40.

Geist BK, Xing H, Wang J, Shi X, Zhao H, Hacker M, et al. A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic 68Ga-FAPI-04 PET/CT imaging. EJNMMI Phys. 2021;8:8.PubMedPubMedCentralCrossRef

41.

Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, et al. Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393–402.PubMedCrossRef

42.

Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48:73–86.PubMedCrossRef

43.

Zhao L, Chen S, Chen S, Pang Y, Dai Y, Hu S, et al. 68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol. 2021;158:55–61.PubMedCrossRef

44.

Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48:1593–603.PubMedCrossRef

45.

Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. Springer; 2020;1–8.

46.

Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48:1604–17.PubMedCrossRef

47.

Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, et al. Comparison of 68 Ga-FAPI and 18 F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393–402.PubMedCrossRef

48.

Moradi F, Iagaru A. Will FAPI PET/CT replace FDG PET/CT in the next decade? Counterpoint—no, not so fast! Am J Roentgenol. 2021;216:307–8.CrossRef

49.

Calais J, Mona CE. Will FAPI PET/CT replace FDG PET/CT in the next decade? Point—an important diagnostic, phenotypic, and biomarker role. Am J Roentgenol. 2021;216:305–6.CrossRef

50.

Guglielmo P, Guerra L. Radiolabeled fibroblast activation protein inhibitor (FAPI) PET in oncology: has the time come for 18F-fluorodeoxyglucose to think to a well-deserved retirement? Clin Transl Imaging. 2021;9:1–2.CrossRef

51.

Hicks RJ, Roselt PJ, Kallur KG, Tothill RW, Mileshkin L. FAPI PET/CT: will it end the hegemony of 18 F-FDG in oncology? J Nucl Med. 2021;62:296–302.PubMedCrossRef

52.

New radiotracers may gain ground in FDG territory. https://www.healthimaging.com/topics/molecular-imaging/nuclear-medicine-tracer-cancerdetection. Accessed 20 May 2021.

53.

Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K, Tsurusaki M, et al. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: An update. Nagoya J Med Sci. 2017;79:527–43.PubMedPubMedCentral

54.

Zhao C, Zhang Y, Wang J. A meta-analysis on the diagnostic performance of (18)F-FDG and (11)C-methionine PET for differentiating brain tumors. AJNR Am J Neuroradiol. American Society of Neuroradiology; 2014;35:1058–65.

55.

Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, et al. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol. 2019;92:20181044.PubMedPubMedCentralCrossRef

56.

Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve J-L, Mitry E, et al. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis Dig Liver Dis. 2015;47:443–54.PubMedCrossRef

57.

Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review). Mol Med Rep. 2015;11:3203–11.PubMedPubMedCentralCrossRef

58.

Mamoor S. FAP is differentially expressed in lymph node metastasis in human breast cancer. OSF Preprints.

59.

Cremasco V, Astarita JL, Grauel AL, Keerthivasan S, MacIsaac K, Woodruff MC, et al. FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors. Cancer Immunol Res. 2018;6:1472–85.PubMedPubMedCentralCrossRef

60.

Pelon F, Bourachot B, Kieffer Y, Magagna I, Mermet-Meillon F, Bonnet I, et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat Commun. 2020;11:404.PubMedPubMedCentralCrossRef

61.

Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3:8.PubMedPubMedCentralCrossRef

62.

Ding F, Huang C, Liang C, et al. 68Ga-FAPI-04 vs.18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Research Square; 2021. https://doi.org/10.21203/rs.3.rs-348458/v1.

63.

Hao B, Wu J, Pang Y, Sun L, Chen H. 68Ga-FAPI PET/CT in assessment of leptomeningeal metastases in a patient with lung adenocarcinoma. Clin Nucl Med Clin Nucl Med. 2020;45:784–6.PubMedCrossRef

64.

Luo Y, Pan Q, Yang H, Li F, Zhang F. Inflammatory arthritis induced by anti-programmed death-1 shown in 68Ga-FAPI PET/CT in a patient with esophageal carcinoma. Clin Nucl Med Clin Nucl Med. 2021;46:431–2.PubMedCrossRef

65.

Foster DS, Nguyen AT, Chinta M, Titan AL, Salhotra A, Jones RE, et al. Cancer-associated fibroblasts persist but show decreased fibroblast activation protein expression after neoadjuvant chemotherapy in human pancreatic ductal adenocarcinoma. J Am Coll Surg Elsevier. 2019;229:S257–8.CrossRef

66.

Ansems M, Span PN. The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiat Oncol Elsevier. 2020;22:90–7.

67.

Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J. Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett Elsevier. 2021;502:84–96.CrossRef

68.

Piper M, Mueller AC, Karam SD. The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy. Mol Carcinog. John Wiley & Sons, Ltd; 2020;59:754–65.

69.

Jin M-Z, Jin W-L. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. Nature Publishing Group; 2020;5:166.

70.

Windisch P, Zwahlen DR, Giesel FL, Scholz E, Lugenbiel P, Debus J, et al. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review. EJNMMI Res. 2021;11:18.PubMedPubMedCentralCrossRef

71.

Gu B, Luo Z, He X, Wang J, Song S. 68Ga-FAPI and 18F-FDG PET/CT images in a patient with extrapulmonary tuberculosis mimicking malignant tumor. Clin Nucl Med Clin Nucl Med. 2020;45:865–7.PubMedCrossRef

72.

Liu H, Wang Y, Zhang W, Cai L, Chen Y. Elevated 68Ga-FAPI activity in splenic hemangioma and pneumonia. Clin Nucl Med; 2021. https://doi.org/10.1097/RLU.0000000000003638.

73.

Hao B, Wu X, Pang Y, Sun L, Wu H, Huang W, et al. [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. Eur J Nucl Med Mol Imaging. Springer; 2021;48:651–2.

74.

Zhu W, Guo F, Wang Y, Ding H, Huo L. 68Ga-FAPI-04 accumulation in myocardial infarction in a patient with neuroendocrine carcinoma. Clin Nucl Med Clin Nucl Med. 2020;45:1020–2.PubMedCrossRef

75.

Notohamiprodjo S, Nekolla SG, Robu S, Villagran Asiares A, Kupatt C, Ibrahim T, et al. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04. J Nucl Cardiol. J Nucl Cardiol; 2021.

76.

Luo Y, Pan Q, Xu H, Zhang R, Li J, Li F. Active uptake of 68Ga-FAPI in Crohn’s disease but not in ulcerative colitis. Eur J Nucl Med Mol Imaging. 2021;48:1682–3.PubMedCrossRef

77.

Wu S, Pang Y, Chen Y, Sun H, Chen H. 68Ga-DOTA-FAPI-04 PET/CT in Erdheim-Chester Disease. Clin Nucl Med Clin Nucl Med. 2021;46:258–60.PubMedCrossRef

78.

Xu T, Zhao Y, Ding H, Cai L, Zhou Z, Song Z, et al. [68Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis. Eur J Nucl Med Mol Imaging. Springer; 2021;48:1254–5.

79.

Pan Q, Luo Y, Zhang W. Idiopathic retroperitoneal fibrosis with intense uptake of 68Ga-fibroblast activation protein inhibitor and 18F-FDG. Clin Nucl Med Clin Nucl Med. 2021;46:175–6.PubMedCrossRef

80.

Hotta M, Sonni I, Benz MR, et al. 68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging; 2021. https://doi.org/10.1007/s00259-021-05373-5.

81.

Can C, Gündoğan C, Güzel Y, Kaplan İ, Kömek H. 68Ga-FAPI uptake of thyroiditis in a patient with breast cancer. Clin Nucl Med. Clin Nucl Med; 2021;Publish Ah.

82.

Zhou Y, He J, Chen Y. 68Ga-FAPI PET/CT imaging in a patient with thyroiditis. Endocrine. Springer; 2021;1–2.

83.

Zhou Y, Yang X, Liu H, Luo W, Liu H, Lv T, et al. Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis. Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging; 2021.

84.

Liu H, Chen Z, Yang X, Fu W, Chen Y. Increased 68Ga-FAPI uptake in chronic cholecystitis and degenerative osteophyte. Clin Nucl Med. Clin Nucl Med; 2021;Publish Ah.

85.

Wu J, Liu H, Ou L, Jiang G, Zhang C. FAPI uptake in a vertebral body fracture in a patient with lung cancer: a FAPI imaging pitfall. Clin Nucl Med Clin Nucl Med. 2021;46:520–2.PubMedCrossRef

86.

Zhang X, Song W, Qin C, et al. Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas. Eur J Nucl Med Mol Imaging; 2021. https://doi.org/10.1007/s00259-021-05194-6.

87.

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med EMBO Mol Med. 2012;4:675–84.PubMedCrossRef

88.

Miao L, Lin CM, Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release J Control Release. 2015;219:192–204.PubMedCrossRef

89.

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115.PubMedCrossRef

90.

Gelardi F, Kirienko M, Sollini M. Climbing the steps of the evidence-based medicine pyramid: highlights from Annals of Nuclear Medicine 2019. Eur J Nucl Med Mol Imaging. 2021;48:1293–301.PubMedCrossRef

91.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of ¹⁷⁷ Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. Massachusetts Medical Society; 2017;376:125–35.

92.

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet Elsevier. 2021;397:797–804.CrossRef

Titel: State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis
verfasst von: Martina Sollini
Margarita Kirienko
Fabrizia Gelardi
Francesco Fiz
Noemi Gozzi
Arturo Chiti
Publikationsdatum: 25.06.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05475-0

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis

Abstract

Introduction

Materials and methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2021

Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study

Current human brain applications and challenges of dynamic hyperpolarized carbon-13 labeled pyruvate MR metabolic imaging

Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging

Fully automated analysis combining [18F]-FET-PET and multiparametric MRI including DSC perfusion and APTw imaging: a promising tool for objective evaluation of glioma progression

Quantitative X-ray phase contrast computed tomography with grating interferometry

New technologies—the best is yet to come